Alira Health Adds CMC Services through Acquisition of Chamow & Associates

Chamow & Associates’ expertise in biopharmaceutical product development expands Alira Health’s lifecycle of healthcare advisory services.   

News
Published on:
January 7, 2021

FRAMINGHAM, Mass. – January 7, 2021 – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, announced it has acquired Chamow & Associates, a California-based integrated CMC advisory firm. This acquisition brings expertise in biologics manufacturing, quality assurance, and regulatory compliance to Alira Health’s Product Development and Regulatory practices, which now offer a full range of services, from discovery to approval, across the U.S. and EU. Chamow & Associates’ Team of Senior Advisors complement Alira Health’s existing offerings with expertise to help clients overcome CMC challenges throughout the development process.

Gabriele Brambilla

“Our mission at Alira Health to enable healthcare transformation and support clients in the earliest stages of development, is critical to efficiently and safely shepherd innovations into the hands of patients,” said Gabriele Brambilla, Chief Executive Officer at Alira Health. Steven Chamow has built a powerful combination of CMC capabilities, technical proficiency, and biologic expertise into his firm. We are proud to welcome them to the Alira Health family, and to offer preclinical and clinical-stage biotechnology companies a lifecycle of solutions to help bring new therapies to patients.”

“We are excited and honored to become part of the Alira Health network, and to join a talented team of experts with a complementary mission,” said Dr. Steven Chamow, President of Chamow & Associates. “Becoming part of the Alira Health family will allow Chamow & Associates to further build our team and greatly expand our work with clients. By adding CMC expertise and advisory to Alira Health’s suite of services, we have a tremendous opportunity to provide comprehensive support to meet the needs of pharmaceutical companies at any stage of the development process.”

 

Steven Chamow will become Alira Health’s Senior Vice President, CMC Development and will lead biopharmaceutical product development.
Lighthouse BioPartners acted as a financial advisor to Chamow & Associates for this transaction.

About Chamow & Associates:
Chamow & Associates is a leading biopharmaceutical consulting company based in the San Francisco Bay Area. Since 2008, the company has provided integrated CMC services, including molecular engineering, process development and manufacturing, quality, regulatory, and project management services, to clinical-stage biotechnology companies around the world. Chamow & Associates focuses on monoclonal antibodies and derivatives, including bispecific antibodies and antibody drug conjugates, in addition to other recombinant protein products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris urna arcu, tempor ut laoreet eu, consectetur in mi. Maecenas rhoncus velit eget metus dignissim, sed bibendum elit lacinia. Mauris tristique, nisi ac sollicitudin dignissim, dui ipsum suscipit nulla, vitae sodales neque mauris vel est. Duis est velit, efficitur eget rutrum non, interdum et erat. Duis elit arcu, tristique quis feugiat quis, tincidunt tempus ligula. In hac habitasse platea dictumst. Ut dolor neque, egestas quis accumsan at, egestas sit amet leo.

Related news

Publications May 25, 2023
The EU Pharmaceutical Package: Introduction to Changes
Alira Health’s Regulatory experts explore how the proposed package will disrupt the European regulatory landscape and what it means for companies.
EU Pharma Regulatory
News February 21, 2023
Access and reimbursement pathways for digital health solutions and IVD devices
Digital therapeutics (DTx) are innovative solutions that use meaningful data to provide evidence-based decisions for the prevention, treatment, and management of diseases. Particular(...)
Diagnostics Digital Therapeutics Market Access Regulatory Research and Development
Events February 10, 2023
Regulatory Roundup
We are pleased to announce that we are joining Regulatory Roundup as sponsors and speakers. This unique event is hosted by MassMEDIC, the largest regional medtech association in the United States.
Regulatory
Events February 2, 2023
ACDM 2023
We are pleased to announce that we will be sponsoring and attending ACDM 2023. ACDM23 offers a full two-day program of expert speakers, specialist panels, workshops and debates which(...)
Clinical Data Science
Blog January 19, 2023
Medical Device Regulation in 2023: A Window of Opportunity
We spoke with our team of regulatory experts about the recent news regarding the MDR and the opportunity it presents to device manufacturers in 2023.
Medical Devices MedTech Regulatory
Blog January 11, 2023
Regulatory Strategy for Registering Rare Disease Products in the EU: What You Need to Know
Given that the regulation is likely to change considerably, drug developers may need to revisit their development strategy. In the meantime, building a strategy around these evergreen(...)
EU Rare Disease Regulatory
Blog December 21, 2022
2022 Recap: Your Favorite Alira Health Publications
In 2022, the Alira Health team of scientists, strategists, economists, clinicians, and biostatisticians shared actionable insights, industry thought leadership, and leading-edge guidance(...)
Clinical Digital Health Market Access MedTech Pharma Regulatory
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.